ReviewMechanisms of ageing and development2026
Circulating elastin fragments drive systemic aging: Where do pro-aging elastin fragments come from? A mini-review.
Review in Mechanisms of ageing and development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Circulating elastin fragments have emerged as potent mediators of inflammaging and systemic aging, yet a fundamental question persists: which anatomical compartments serve as the primary sources of these fragments during aging? Elastin is a structurally restricted protein distributed unevenly across tissues, predominantly at sites subject to repetitive mechanical loading, such as the aorta and large arteries, the lungs, and the skin. It is speculated that age-driven structural deterioration within these compartments, spanning arteriosclerosis, emphysema, and dermal extracellular matrix (ECM) remodeling, coupled with upregulated elastolytic protease activity (including neutrophil elastase, MMP-2, MMP-9, and MMP-12), sustains a chronic, low-grade release of bioactive elastin fragments into the circulation, thereby fueling inflammaging and systemic aging. Delineating the relative contributions of each source is therefore more than an anatomical exercise; it establishes a mechanistic framework for designing tissue-targeted interventions capable of disrupting the ECM-inflammaging axis. This mini-review examines the principal anatomical sources of circulating elastin fragments and the elastolytic enzymes responsible for their generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.